Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1900 +0.0028 (+1.50%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.1900 unch (unch) 19:46 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1705
Day High
0.1921
Open 0.1800
Previous Close 0.1872 0.1872
Volume 1,826,600 1,826,600
Avg Vol 1,818,075 1,818,075
Stochastic %K 33.58% 33.58%
Weighted Alpha -88.52 -88.52
5-Day Change -0.0008 (-0.42%) -0.0008 (-0.42%)
52-Week Range 0.1701 - 1.2500 0.1701 - 1.2500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,268
  • Shares Outstanding, K 173,662
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -37,450 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.58
  • Price/Sales 12.90
  • Price/Cash Flow N/A
  • Price/Book 1.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings $-0.20 on 03/25/25
  • Next Earnings Date 05/01/25 [BMO]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 516.72% ( -180.18%)
  • Historical Volatility 82.63%
  • IV Percentile 98%
  • IV Rank 73.61%
  • IV High 696.91% on 04/24/25
  • IV Low 14.18% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 28,063
  • Open Int (30-Day) 28,368

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.02
  • Low Estimate -0.19
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1701 +11.70%
on 04/24/25
Period Open: 0.2594
0.2847 -33.26%
on 03/27/25
-0.0694 (-26.75%)
since 03/25/25
3-Month
0.1701 +11.70%
on 04/24/25
Period Open: 0.4775
0.8142 -76.66%
on 01/30/25
-0.2875 (-60.21%)
since 01/24/25
52-Week
0.1701 +11.70%
on 04/24/25
Period Open: 1.1300
1.2500 -84.80%
on 04/29/24
-0.9400 (-83.19%)
since 04/25/24

Most Recent Stories

More News
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Announces Reverse Stock Split

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals: Q4 Earnings Snapshot

X4 Pharmaceuticals: Q4 Earnings Snapshot

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.1900 (+1.50%)
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

XFOR : 0.1900 (+1.50%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 0.2195
2nd Resistance Point 0.2058
1st Resistance Point 0.1979
Last Price 0.1900
1st Support Level 0.1763
2nd Support Level 0.1626
3rd Support Level 0.1547

See More

52-Week High 1.2500
Fibonacci 61.8% 0.8375
Fibonacci 50% 0.7100
Fibonacci 38.2% 0.5826
Last Price 0.1900
52-Week Low 0.1701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective